AzTrials
AzTrials

Energy Supply; DeficiencyNCT05551455

Endocrinological and Physiological Responses to Short-term Reduced Carbohydrate Availability in Males

A study testing Nutritional/dietary intake manipulation ('Normal') and Nutritional/dietary intake manipulation ('Low') in people with Energy Supply; Deficiency and Carbohydrate Availability, run by Liverpool John Moores University at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Using a randomised crossover design, nine weight-stable men, aged 18 - 40 years old, will be recruited via convenience sampling from the staff and student body of LJMU and local area. Read more about this study

Who is it for?
Ages 18 to 40 years, men onlyHealthy volunteers can take part
What is being tested?
Nutritional/dietary intake manipulation ('Normal') and Nutritional/dietary intake manipulation ('Low')
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
1 siteUnited Kingdom
Study dates
4 May 2022to 9 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Gender/Sex: Male
  • Age:18-40
  • Healthy (as determined by pre-participation questionnaires)
  • Regularly Exercising/Aerobically trained (3 + times/week, VO2max >50 ml/kg/min), as determined through participant self-identification via recruitment email/verbal communication and baseline assessment of VO2max)
  • Weight-stable (within 2 kg) for the past 6-months

Who cannot join

  • Gender/Sex: Female/Other
  • Age - < 18 - > 40
  • Health - Deemed unable to perform exercise (assessed via PAR-Q)
  • Current smoker.
  • Medical Condition - Those with any previous diagnosis of; Osteoporosis/low bone mineral density, cardio-vascular disease, Diabetes Mellitus, Cerebrovascular Disease, blood-related illness/disorder, Asthma or other respiratory illness/disorder, Liver Disease, Kidney Disease, gastrointestinal disease, Eating Disorder or Disordered Eating. Those currently taking prescription medication or unwell with a cold or virus at the time of participation.
  • Those unwilling to adhere to the study's methodological requirements (including adhering to alterations in diet and training - inc. alcohol abstention) from the day prior to intervention onset (24 hrs pre-intervention) to completion of follow-up assessments (day 5).
Show all 10Show fewer
  • Those following a restrictive diet (e.g. vegans)
  • Those with food allergies and/or food intolerances
  • Training status - Does not train 3 + times/week (over past 6 months on average) and/or have a VO2max >50 ml/kg/min.
  • Any athletes that may be tested for substances on the WADA banned substances list

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Liverpool John Moores University

    Liverpool, Merseyside, L3 3AF

Other trials in United Kingdom

About this study

Official title: Investigating the Endocrinological and Physiological Responses to Short-term Reduced Carbohydrate Availability in Males.

Using a randomised crossover design, nine weight-stable men, aged 18 - 40 years old, will be recruited via convenience sampling from the staff and student body of LJMU and local area. Participants will be asked to follow two 4-day (~96 hours) periods of tightly controlled exercise energy expenditure (15 kcal/kg FFM/day [cycling]) and dietary intake (60 kcal/kg FFM/day) to compare a state of 'normal' energy availability (or energy balance; equivalent to 45 kcal/kg FFM/day) with concomitant 1: normal carbohydrate availability ('Normal'; ~60% of dietary intake from carbohydrate) and 2: low carbohydrate availability ('LCHF', ~1.5 g/kg carbohydrate per day, ~70 - 80% dietary intake from fat). This approximates the amount of carbohydrate consumed by an individual in a state of LEA through consuming 10 kcal/kg FFM/day with 50% of intake from carbohydrate, or ~1.5 g/kg/day of carbohydrate. In both experimental phases we will measure endocrine, metabolic and physiological parameters.

Read the detailed description

Rationale:

The primary research question associated with this study is 'What is the impact of an acute period of low carbohydrate availability upon associated physiological and endocrinological markers in a cohort of healthy males?'

Extensive research has been conducted since the 1970s to determine the aetiology behind the concurrent impairment of reproductive function and low bone mineral density that is commonly observed in exercising females (De Souza et al., 2014). This research has determined that chronic low energy availability ('LEA' - the energy available from diet after energy used in exercise has been subtracted) is the key determining factor for the endocrine and physiological responses observed in the Female Athlete Triad (De Souza et al., 2014) model. However, whilst the Male Athlete Triad (Nattiv et al., 2021) and RED-S (Mountjoy et al., 2018) models identify the likely impact of LEA upon males, equivalent research identifying the physiological effects of this state in males is far behind that of females.

Moreover, whilst low energy availability has been identified as the key driver of the physiological dysregulations identified in the Female/Male Athlete Triad and RED-S models, much of the existing research has not adequately delineated between the impact of low energy availability, per se, and low carbohydrate availability. Recent research suggests that low carbohydrate availability, with or without the presence of LEA, may be a driver of the physiological dysregulations identified within the aforementioned models. For example, McKay et al (2021) have shown altered iron and immune responses and impaired exercise performance following 6-days of low carbohydrate (50 - 100 g/day) but ~normal energy availability (40 kcal•kg FFM-1•day-1), whilst no changes were apparent in a LEA (15 kcal•kg FFM-1•day-1, 60% carbohydrate) and a control group. Similarly, Heikura et al (2020) have recently shown that over 3.5 weeks, a ketogenic diet impairs markers of bone turnover compared to an energy-matched high carbohydrate diet in highly trained athletes.

Given that exercise and nutritional interventions are key for improving weight-loss and health of the general population, understanding how reduced energy and/or carbohydrate availability may affect male endocrinology and physiology is of the utmost importance. The effects and mechanisms by which low energy and/or carbohydate availability influences male physiological function therefore requires further research using well-controlled experimental research designs.

We have recently conducted a study that aimed to understand the broad physiological, endocrine and muscular responses to a period of five-days of low energy availability (analysis of samples is ongoing). The proposed study therefore now aims to extend the scope of our research to investigate the impact of four- days of low carbohydrate availability using a low-carbohydrate, high-fat diet in the presence of adequate energy availability to address this gap in the literature.

Objectives:

Primary:

To investigate the physiological responses of adult males to low carbohydrate availability whilst in energy balance over 4-days (~96 hrs, spanning five testing mornings), in contrast to an equivalent period of controlled energy balance with 'normal' carbohydrate availability in relation to muscle and endocrine parameters.

Secondary:

To investigate the wider physiological responses of adult males to low carbohydrate availability (whilst in energy balance) over 4-days (~96 hrs, spanning five testing mornings), compared to an equivalent period in controlled 'normal' carbohydrate availability in relation to whole-body physiological and metabolic status as well as body composition changes.

Study Methods:

Using a randomised cross-over design, participants will complete two interventions that will elicit conditions of 'normal' (NEA) and 'low' (LEA) carbohydrate availability whilst in energy balance, with a 10-day washout period in between conditions. Body composition changes and markers of bone turnover and reproductive health will be assessed, along with further physiological parameters.

Sample Size:

Sample size was determined based upon the primary outcome measure of Free Circulating Testosterone, the least sensitive primary outcome measures of the study.

The findings of Koehler et al (2016) were used to estimate required sample size for this study. Koehler et al (2016) reported a non-significant (P >0.05) change in Testosterone following four days of Low Energy Availability (with exercise) at 15 kcal/kg FFM/day (LEA + Ex: Pre 5.27 ± 0.46, Post 4.46 ± 0.96 ng.ml-1), compared to a control group with exercise (C + Ex: Pre 4.98 ± 0.47 Post 4.92 ± 0.53 ng.ml-1). However, a large effect size for the reduction in testosterone concentrations for LEA + Ex compared to C + Ex (d = 1.36) was observed/calculated. Therefore a post-hoc power analysis was conducted, revealing a power (1-β err probability) of 0.759 for the sample size of N = 6. To replicate these findings with greater statistical power (α err prob 0.05, 1-β err prob > 0.9) would require 8 participants, with 9 participants required to factor for a potential 10% dropout rate in participants commonly observed.

Quality:

The research plan has been reviewed internally within the research team at Liverpool John Moores University. The researcher's associated with this study and associated with the review of the study protocol are all members of staff (or a PhD Student) within the Liverpool John Moores University Research Institute for Sport \& Exercise Sciences (RISES). In the 2014 RISES (LJMU) submitted 34.75 FTE (full time equivalent) to Unit of Assessment 26 (UoA26) and attained a GPA (Grade Point Average) of 3.57. Placed second on GPA in the UoA, RISES became the leading centre for Sport and Exercise Science Research Quality in the UK (4* - 61% of all activity world leading, 3* - 36% of all activity internationally excellent standard). RISES submitted the largest volume of 4* outputs (n=60) in the UoA, had 90% of the impact activity rated at 4* and had 100% of the environment rated as 4*. Importantly, out of 1,911 submissions in all 36 UoA's RISES came 11th in the entire UK for GPA achieved at REF2014, putting RISES (LJMU) amongst Oxford, UCL, LSE and Cambridge in the league tables for this metric. This makes RISES perfectly qualified to assess this research project.

Being tested
Nutritional/dietary intake manipulation ('Normal'), Nutritional/dietary intake manipulation ('Low')
Keywords
Bone turnover markers, Testosterone, Glucose, Glycerol, Ketones, Insulin, Leptin, Ghrelin, Triglycerides, Triiodothyronine, Thyroxine, Resting Metabolic Rate (RMR), Free fatty acids, Blood pressure, ß-CTX, P1NP
Medical subject headings
Ketosis, Insulin Resistance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nutritional/dietary intake manipulation ('Normal')Other

    Also called Normal Carbohydrate Availability

    Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.

  • Nutritional/dietary intake manipulation ('Low')Other

    Also called Low Carbohydrate Availability

    Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).

Study groups in NCT05551455
Study groupRoleWhat they receive
Normal Carbohydrate AvailabilityOtherParticipants will complete a supervised morning cycling session daily (each morning for five days) to achieve a 15 kcal/kg FFM/day exercise energy expenditure, with samples collected pre-, during- and post-exercise. Participants will then be provided (daily) with all subsequent dietary intake for the intervention period. In the Normal Carbohydrate Availability trial arm, participants will be provided with 60 kcal/kg FFM/day of energy intake, to elicit a net energy availability of 45 kcal/kg FFM, with ~60% of this energy intake from carbohydrates. The intervention will last for four days, spanning five testing mornings (i.e. trial begins following fasted baseline assessments on morning 1, finishing with final sample collection on morning 5).
Receives: Other: Nutritional/dietary intake manipulation ('Normal')
Low Carbohydrate AvailabilityExperimentalParticipants will complete a supervised morning cycling session daily (each morning for five days) to achieve a 15 kcal/kg FFM/day exercise energy expenditure, with samples collected pre-, during- and post-exercise. Participants will then be provided (daily) with all subsequent dietary intake for the intervention period. In the Low Carbohydrate Availability trial arm, participants will be provided with 60 kcal/kg FFM/day of energy intake, to elicit an energy availability of 45 kcal/kg FFM, with ~1.5 g/kg provided from carbohydrate and ~70-80% of energy intake in the form of fat. The intervention will last for four days, spanning five testing mornings (i.e. trial begins following fasted baseline assessments on morning 1, finishing with final sample collection on morning 5).
Receives: Other: Nutritional/dietary intake manipulation ('Low')

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in blood bone turnover markers: ß-CTX (Bone Resorption)

    Analysis of changes in blood-borne bone (re)modelling marker ß-CTX (Bone Resorption) following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  2. Changes in blood bone turnover markers: P1NP (Bone Formation)

    Analysis of changes in blood-borne bone (re)modelling marker P1NP (Bone Formation)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  3. Changes in blood metabolites/hormones: Testosterone

    Analysis of changes to circulating testosterone concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

Secondary outcomes (37)
  1. Change in resting substrate utilisation

    Analysis of changes in resting substrate utilisation. Assessed using indirect calorimetry.

    Measured: Days 1, 3 and 5 of each intervention

  2. Changes in sub-maximal Exercise Energy Expenditure

    Analysis of changes in sub-max exercise energy expenditure and substrate utilisation at standardised exercise intensities. Assessed using indirect calorimetry.

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  3. Changes in sub-maximal exercise substrate utilisation

    Analysis of changes in sub-max exercise energy expenditure and substrate utilisation at standardised exercise intensities. Assessed using indirect calorimetry.

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  4. Immune function

    Analysis of changes to saliva-based markers of immune function

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  5. Changes in Initial Orthostatic Hypotension (IOH)

    Analysis of changes in IOH, assessed via blood pressure finometry and questionnaire

    Measured: Pre- and post-intervention (days 1 and 5) for both intervention

  6. Change in Profile of Mood States

    Analysis of changes in Psychological/mood, assessed via the POMS-40 questionnaire

    Measured: Pre- and post-intervention (days 1 and 5) per intervention

  7. Change in subjective hunger

    Analsis of changes in subjective hunger, assessed via visual analogue scales

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  8. Change in sexual drive/libido

    Analysis of subjective sex-drive/libido changes, assessed via visual analogue scale

    Measured: Pre- and post-intervention (days 1 and 5)

  9. Physical activity energy expenditure (PAEE)

    Analysis of PAEE alterations, assessed via wrist-worn accelerometers (acti-watch)

    Measured: Continuous monitoring during intervention period (5-days)

  10. Sleep duration and quality

    Analysis of sleep alterations, assessed via wrist-worn device and sleep diary (collectively quantified by analysis of sleep duration, sleep latency, time of sleep onset, no of wakes during night, subjective sleep quality visual analogue scale)

    Measured: Continuous monitoring during intervention period (5-days)

  11. Changes in Body Composition: Body Mass (kg)

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  12. Changes in Body Composition: Body Mass Index (kg/m^2)

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  13. Changes in Body Composition: Fat Mass (kg)

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  14. Changes in Body Composition: Body Fat Percentage (%)

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  15. Changes in Body Composition: Fat Free Mass (kg)

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  16. Changes in Body Composition: Skeletal Muscle Mass (kg)

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  17. Changes in Body Composition: Total Body Water (l)

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  18. Changes in Body Composition: Total Body Water (%)

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  19. Changes in Body Composition: Extra-cellular Water (l)

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  20. Changes in Body Composition: Extra-cellular Water (%)

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  21. Changes in Body Composition: Extra-cellular Water/Total Body Water ratio

    Analysis of body composition changes - assessed using bio-electrical impedance analysis (BIA)

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  22. Changes in blood metabolites/hormones: Ketones

    Analysis of changes to circulating ketones concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  23. Changes in blood metabolites/hormones: Glucose

    Analysis of changes to circulating glucose concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  24. Changes in blood metabolites/hormones: Free fatty Acids

    Analysis of changes to circulating free fatty acid concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  25. Changes in blood metabolites/hormones: Insulin

    Analysis of changes to circulating insulin concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  26. Changes in blood metabolites/hormones: Cortisol

    Analysis of changes to circulating cortisol concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  27. Changes in blood metabolites/hormones: HDL

    Analysis of changes to circulating HDL concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  28. Changes in blood metabolites/hormones: LDL

    Analysis of changes to circulating LDL concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  29. Changes in blood metabolites/hormones: glycerol

    Analysis of changes to circulating glycerol concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  30. Changes in blood metabolites/hormones: Leptin

    Analysis of changes to circulating Leptin concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  31. Changes in blood metabolites/hormones: IGF-1

    Analysis of changes to circulating IGF-1 concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

  32. Alterations to skeletal muscle glycogen

    Assessment of alterations in skeletal muscle glycogen content

    Measured: Days 1 & 5 per intervention (pre-post)

  33. Alterations to Intra-muscular lipid profile: lipid droplet content

    Assessment of alterations in lipid droplet content

    Measured: Days 1 & 5 per intervention (pre-post)

  34. Alterations to Intra-muscular lipid profile: lipid droplet morphology

    Assessment of alterations in lipid droplet morphology

    Measured: Days 1 & 5 per intervention (pre-post)

  35. Alterations to Intra-muscular lipid profile: lipid droplet associated proteins

    Assessment of alterations in lipid droplet associated proteins

    Measured: Days 1 & 5 per intervention (pre-post)

  36. Resting Metabolic Rate

    Analysis of changes to Resting Metabolic Rate (kcal/day) following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 3 and 5 of each intervention

  37. Changes in blood metabolites/hormones: Triiodothyronine (T3)

    Analysis of changes to circulating T3 concentrations following short term energy balance with a) normal carbohydrate availability and b) low carbohydrate availability

    Measured: Days 1, 2, 3, 4 & 5 per intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Sep 2022
  2. Study start4 May 2022
  3. Primary completion9 Dec 2022
  4. Study completion9 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Model description
Participants will complete two five-day trial-arms in randomised order, with an \~10-day washout period between interventions.
Masking
None (open label)
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05551455
Sponsor's protocol ID
22/SPS/026
Status last verified
Oct 2023
First submitted
2 Mar 2021
Last updated
17 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Nutritional/dietary intake manipulation ('Normal') and Nutritional/dietary intake manipulation ('Low') in people with Energy Supply; Deficiency and Carbohydrate Availability, run by Liverpool John Moores University at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in blood bone turnover markers: ß-CTX (Bone Resorption) (time frame: Days 1, 2, 3, 4 & 5 per intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in